Josh Makower

Dr. Josh Makower is an endowed Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and is the Director and Co-Founder of the Stanford Byers Center for Biodesign. He also serves as a Special Partner on New Enterprise Associate’s healthcare team and plays an active role in their medtech/healthtech practice. Dr. Makower is the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 20 years, including Revelle Aesthetics.

Notable transactions from the ExploraMed portfolio include NeoTract; acquired by Teleflex in 2017, Nuelle; acquired by Aytu in 2017, Acclarent; acquired by J&J in 2009, EndoMatrix; acquired by C.R. Bard in 1997 and TransVascular; acquired by Medtronic in 2003. On-going ExploraMed/NEA ventures include Moximed, Willow and ExploraMed V. Dr. Makower currently serves on the board of directors for DOTS Devices, Eargo (NASDAQ: EAR), ExploraMed, Allay Therapeutics, Intrinsic Therapeutics, Lungpacer, Moximed, Willow, SetPoint Medical and Coravin.

Dr. Makower holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, plastic surgery, dermatology, aesthetics, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.